Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BR-DIM in Systemic Lupus Erythematosus
NCT02483624Phase 1Terminated
- Sponsor
- Northwell Health
- Start
- Jan 2016
- Primary completion
- Jan 2016
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, single-blind trial of 3,3'-diindolylmethane in systemic lupus erythematosus (SLE) (3 arms), sponsored by Northwell Health. Primary endpoints: Safety and Tolerability Routine clinical and laboratory parameters as well as SLE activity measurement with SELENA Systemic Lupus Erythematosus Disease Activity Index assessment at 14 months, Estradiol Hydroxylation Pathways at 14 months and 2 more. Started Jan 2016; status: terminated.
02
Drugs
3,3'-diindolylmethane
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02483624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02483624.